title: A comparison of immunomodulation therapies in mechanically ventilated patients with Guillain Barré syndrome.
abstract: A comparison of the effectiveness of immunomodulatory therapies in patients with Guillain Barré syndrome (GBS) who require mechanical ventilation (MV) is important for patient treatment and cost. We aimed to compare the effectiveness of three modes of intervention on the outcome of patients with GBS receiving MV: intravenous immunoglobulin (IVIgG); small volume plasmapheresis (SVP) and large volume plasmapheresis (LVP). Patients with GBS satisfying National Institute of Neurological and Communicative Disorders and Stroke 1990 criteria and requiring MV between 1997 between 2007 were analyzed. The primary outcome parameters evaluated were mortality, duration of MV, hospital stay and Hughes scale at discharge from hospital. Of the 173 (Male: Female, 118:55) patients who required MV during the study, 106 patients received single modality treatment (IVIgG 31, LVP 45, SVP 30) based on availability, affordability and feasibility. Patients receiving IVIgG had a higher incidence of severe weakness and bulbar involvement. The mean duration of MV (p=0.61), total hospital stay (p=0.44) and Hughes scale at discharge (p=0.31) did not differ among the three groups. Complications were similar in the three treatment groups except for hypoalbuminemia and anemia, which were more common in patients in the LVP group. In conclusion, the outcome of patients treated with these three immunomodulatory treatment modalities did not vary. The beneficial effects of SVP in our study warrant further randomized control trials especially in resource-constrained settings.
authors.affiliation: Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore 560 029, Karnataka, India.
authors.forename: Archana B
authors.initials: AB
authors.lastname: Netto
authors.forename: Girish Baburao
authors.initials: GB
authors.lastname: Kulkarni
authors.forename: Arun B
authors.initials: AB
authors.lastname: Taly
authors.forename: Gs Umamaheshwara
authors.initials: GU
authors.lastname: Rao
authors.forename: Sunder
authors.initials: S
authors.lastname: Periyavan
authors.forename: Shivaji
authors.initials: S
authors.lastname: Rao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005260:Female; D020275:Guillain-Barre Syndrome / Q000401:mortality / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis; D012121:Respiration, Artificial
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors